trending Market Intelligence /marketintelligence/en/news-insights/trending/t0alawhizcvyblst1vjdpw2 content esgSubNav
In This List

Karyopharm Therapeutics elects director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Karyopharm Therapeutics elects director

Newton, Mass.-based biotechnology company Karyopharm Therapeutics Inc. elected F. Carsten Thiel as a Class II director.

Thiel's term will expire at the company's 2021 annual meeting of stockholders.

Karyopharm's board increased the number of directors comprising the board to eight from seven and increased the number of Class II directors to two in connection with Thiel's appointment.